Swiss pharmaceutical major Hoffmann-La Roche's patents rights over Hepatitis C drug Pegasys has been challenged by public interest groups at the Indian Patent Office.
The first off the block appears to be the Reliance Anil Dhirubhai Ambani Group (R-ADAG), which is investing Rs 1,200 crore (Rs 12 billion) in setting up a large drug distribution backbone.
The six-decade-old pharmaceutical company VHB Life Sciences will come out with an initial public offer in July this year to fund its Rs 400-crore
Alkem, the largest manufacturer of Fructo-Oligo Saccharides, which helps the growth of good probiotic bacteria, is planning to roll out more products in the national and global markets, said Sharad.
Reliance Pharmaceuticals, the proposed pharmaceutical manufacturing company promoted by Mukesh Ambani's Reliance Life Sciences, will soon rope in a consultant to give final shape to the project, slated to take off within two years.
Elder Healthcare, an associated company of Elder Pharmaceuticals, will soon sign an inlicensing agreement with the Thailand-based herbal drug and personal care products manufacturer FCP Company to launch its products in India.
The World Health Organisation and the International Pharmaceutical Federation have joined hands with the Indian Pharmaceutical Association -- the national body of pharmacists in the country -- to upgrade the quality of services of 5.5 lakh pharmacies
Pharmaceutical industry experts said the US move had come as a boon for the Indian drug exporters as the law could clear the alleged doubts on the quality and the genuineness of Indian pharmaceutical and raw material products.
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
The world's largest manufacturer of healthcare products, Johnson & Johnson, is making India a global hub of its research and development as it looks to ramp up its pharmaceutical business in the country.
The increasing number of generic players tapping the US market for known molecules has resulted in pricing pressures and lean margins.
D Aravindakshan was the managing director of Kerala State Drugs and Pharmaceuticals at Alleppey for many years before taking over as the head of Agastya Biopharma
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
The Bangalore-based Himalaya Herbal Healthcare has struck strategic alliances with leading retail chains in its main export markets such as the US, Singapore and Malaysia.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
In a fresh round of patent battle over the launch of generic drugs in the US market, domestic pharmaceutical majors Orchid, Sun Pharma and Ranbaxy Laboratories have been sued by Cima Labs, Otsuka Pharmaceutical Co and Abbott Laboratories, respectivel
Fortis Healthcare, promoted by the Singh family of Ranbaxy, plans to expand its network to 40 hospitals within three years by either acquiring new facilities or setting up greenfield projects
Beer is gaining more popularity in some of the non-traditional beer markets in North India like Rajasthan, Punjab, Delhi and Uttar Pradesh.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances